Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + S-1 in advanced gastric cancer
NCT02525237Phase 2Unknown
- Sponsor
- Qingdao Municipal Hospital Group
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Qingdao Municipal Hospital Group. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02525237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525237.